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ole of Adenosine in
cute Myocardial Infarction
he Acute Myocardial Infarction STudy of ADenosine (AMISTAD
I) is a pivotal trial having major clinical implications for the
reatment of patients with acute myocardial infarction (AMI) (1).
he AMISTAD II study corroborates the findings of the first
MISTAD study (2); it verifies that, as in animals (3), myocardial
eperfusion injury significantly contributes to final infarct size in
umans, and demonstrates that reperfusion injury accounts for
50% of the final infarct size after reperfusion.
Several issues regarding the design of the AMISTAD II study
hould be addressed. First, the study was severely underpowered.
his was further compounded by having a second treatment arm
ith low-dose adenosine. The rationale for the second arm is
nclear as the first AMISTAD study clearly shows that high-dose
denosine (70 g/kg/min) is efficacious with regard to reducing
nfarct size in patients with anterior AMI and does not cause
erious adverse clinical events (2).
Second, because the beneficial effects of adenosine in experi-
ental models occur only with reperfusion, adenosine should
ttenuate reperfusion injury only in reperfused patients. In the
MISTAD II study approximately 60% of the patients were
reated with thrombolytic agents, with streptokinase used in
lmost 40% of these patients. This would result in only approxi-
ately 80% of patients undergoing successful reperfusion. A subset
nalysis of the primary clinical end points in the high-dose group
ho underwent successful reperfusion may show a significant
ifference. This hypothesis is supported by the observation, pre-
ented in abstract form, that the combined clinical end point of
eath and congestive heart failure was significantly reduced in the
ooled adenosine group (low  high dose) who underwent
5uccessful reperfusion (placebo 15% vs. pooled adenosine 11%; p
.04), whereas no significant difference was found in patients who
id not reperfuse (placebo 34% vs. pooled adenosine 33%; p 0.7)
4).
Third, because animal studies demonstrate that adenosine’s
eneficial effects are lost if myocardial ischemia occurs for more
han 3 h (5), adenosine would prevent reperfusion injury only in
atients receiving adenosine within the first 3 h after coronary
cclusion. Therefore, a subset analysis of the high-dose group who
ere reperfused within 3 h may yield an even greater reduction in
linical end points. Indeed, data from the abstract presentation
how strong trends in the combined end points in the pooled
denosine group treated within 2 h of symptoms (pooled adenosine
% vs. placebo 13%) (4). This is further supported by the study of
arzilli et al. (6) in which patients undergoing mechanical
eperfusion within 2 h of symptoms and who were treated with
denosine showed a significant improvement in ventricular func-
ion and a reduction in major adverse clinical end points.
Despite these shortcomings, the AMISTAD II study, taken in
onjunction with other clinical studies with adenosine, has impor-
ant implications for the treatment of AMI. Adenosine is the only
gent that has been shown consistently to reduce infarct size and,
n some studies, to improve clinical outcomes in AMI patients
ndergoing reperfusion therapy. Adenosine should therefore be
dded to the armamentarium of agents used to treat patients with
MI who are candidates for either pharmacologic or mechanical
eperfusion strategies.
ervyn B. Forman, MD, PhD, FACC
Edwin K. Jackson, PhD
Center for Clinical Pharmacology
niversity of Pittsburgh School of Medicine
00 Technology Drive
uite 450
ittsburgh, Pennsylvania 15219-3130
-mail: edj@pitt.edu
doi:10.1016/j.jacc.2005.12.039
lease note: Vanderbilt University owns intellectual property related to adenosine
nd myocardial infarction that was invented by Drs. Forman and Jackson some
5 years ago.
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MISTAD Trials: Possible
easons for Lack of Success
esults of the Acute Myocardial Infarction STudy of ADenosine
AMISTAD II) trial were recently reported by Ross et al. (1). As
n the AMISTAD I trial (2), most of the conclusions were at best
quivocal, although subgroup analysis each time suggested aden-
sine might be useful as an adjunct to reperfusion therapy in
ertain patients with acute myocardial infarction. Thus the hope
as raised that a more targeted trial might yield a significant
ifference between placebo and treatment groups. Although this
ossibility is real, we would like to offer an alternative hypothesis.
ontrary to the twice-repeated assertion by the investigators that
adenosine . . . has consistently provided myocardial protection
rom ischemic injury in animal models,” the ability of adenosine
dministered at or shortly before reperfusion to provide cardiopro-
ection against infarction is indeed quite controversial. There are
ertainly some studies which report that adenosine at reperfusion
an decrease infarct size in various animal models, and some of
hese experimental investigations are acknowledged by Ross et al.
1). However, it is notable that two of the references cited by the
esearchers to justify their conclusion have been misquoted. Yao
nd Gross (3) and Thornton et al. (4) found protection when
denosine or an adenosine agonist was used as a preconditioning
gent.
Furthermore, Thornton et al. (4) actually observed that when
6-(2-phenylisopropyl) adenosine (PIA) was infused at reperfu-
ion, it had no cardioprotective effect despite its effectiveness when
pplied as a pretreatment. Also, numerous other preclinical studies
ave been unable to document an effect of authentic adenosine
5–8) at reperfusion on infarct size. Therefore, it is possible that
oth the inability to demonstrate a significant effect of adenosine
t reperfusion in patients and the inconsistent preclinical results are
ecause adenosine given at reperfusion simply does not protect the
eart.
In the two AMISTAD trials it was reported that infarct size
as significantly diminished in those patients with anterior wall
yocardial infarction who were treated with adenosine. Although
his observation is potentially important and noteworthy, a tech-
ical limitation diminishes the significance of the data. It has been
ecognized for many years that a major determinant of infarct size
s the size of the region at risk. In fact, no experimental study of
nfarct size limitation would be accepted for publication if the size
f the risk region were not quantitated and used to normalize the
easurement of infarct size. It is recognized that it is difficult, but
ot impossible, to obtain these data in clinical studies because
cans must be recorded both before and after the intervention.
eliance on absolute infarct size as a percentage of the left
entricle—despite the many reasonable correlations between this
arameter and measures of ventricular function and clinical out-
ome, without normalization for the size of the region at risk—can
ield incorrect conclusions. And this difficulty is perhaps best
ighlighted by the very different measurements of infarction in
atients treated with placebo: 45% in the AMISTAD I study and
7% in the AMISTAD II study. dMichael V. Cohen, MD
ames M. Downey, PhD
Department of Physiology
SB 3050
niversity of South Alabama
ollege of Medicine
obile, Alabama 36688
-mail: mcohen@usouthal.edu
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EPLY
e thank Drs. Cohen and Downey for their interest in our report
n treatment of anterior myocardial infarction with adenosine (1).
e do not agree that we misquoted Yao and Gross (2) and
hornton et al. (3) with respect to the cardioprotective effects of
denosine. The Thornton et al. study was cited, with others, in
tating that “adenosine has consistently provided myocardial pro-
ection from ischemic injury.” The Yao and Gross study (2)
upports the statement that “adenosine and adenosine agonists are
yocardial protectants.” We did not say that this protection was
pecifically related to the time of reperfusion, as implied. The
eduction in infarct size may have been related also to other
alutary effects of adenosine. In many patients the drug was on
oard during at least part of the time of coronary occlusion, and
hus it might have a protective effect during ischemia. Certainly, in
hose receiving thrombolytic therapy, there was a time lag between
dministration of the lytic and when reperfusion was complete.
hus, it is possible that adenosine played a protective role during
his time of continuing ischemia.
We do not agree that the difference in infarct size in the
MISTAD I and AMISTAD II studies somehow imputes the
eliability of the single-photon emission computed tomography
ata in the AMISTAD II study. The validity of SPECT infarct
